Anti-IgE monoclonal antibody, omalizumab: A new treatment for allergic asthma

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 2, 2004, Pages 439-446

  Chung, K Fan ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Allergic asthma; Anti IgE monoclonal antibody; Omalizumab

Indexed keywords

ALLERGEN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; FLUTICASONE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; MONOCLONAL ANTIBODY; OMALIZUMAB; PLACEBO;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BASOPHIL; BINDING AFFINITY; CHILD; CLINICAL TRIAL; COMORBIDITY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; EOSINOPHIL; HIGH RISK PATIENT; HUMAN; INFLAMMATION; MORBIDITY; PEAK EXPIRATORY FLOW; PHARMACODYNAMICS; QUALITY OF LIFE; RECEPTOR BINDING; SCORING SYSTEM; SIDE EFFECT; T LYMPHOCYTE;

ALLERGENS; ANTIBODIES, MONOCLONAL; CHILD; DRUG EVALUATION; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY HYPERSENSITIVITY;

EID: 1242341925     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.2.439     Document Type: Article

References (47)

1. ISHIZAKA K, ISHIZAKA T: Physicochemical properties of reaginic antibody. 1. Association of reaginic activity with an immunoglobulin other than γA- or γG-globulin. J. Allergy (1966) 37:169-185.
2. JOHANSSON SG, BENNICH H: Immunological studies of an atypical (myeloma) immunoglobulin. Immunology (1967) 13:381-394.
3. POLLART SM, CHAPMAN MD, FIOCCO GP, ROSE G, PLATTS-MILLS TA: Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits. J. Allergy Clin. Immunol. (1989) 83:875-882.
4. BURROWS B, MARTINEZ FD, HALONEN M, BARBEE RA, CLINE MG: Association of asthma with serum IgE levels and skin-test reactivity to allergens. N. Engl. J. Med. (1989) 320:271-277.
5. SEARS MR, BURROWS B, FLANNERY EM, HERBISON GP, HEWITT CJ, HOLDAWAY MD: Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N. Engl. J. Med. (1991) 325:1067-1071.
6. PEAT JK, TOELLE BG, DERMAND J, VAN DEN BR, BRITTON WJ, WOOLCOCK AJ: Serum IgE levels, atopy, and asthma in young adults: results from a longitudinal cohort study. Allergy (1996) 51:804-810.
7. GREEN JM: The B7/CD28/CTLA4 T-cell activation pathway. Implications for inflammatory lung disease. Am. J. Respir. Cell Mol. Biol. (2000) 22:261-264.
8. KAPLAN MH, SCHINDLER U, SMILEY ST, GRUSBY MJ: Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity (1996) 4:313-319.
9. HERSHEY GK, FRIEDRICH MF, ESSWEIN LA, THOMAS ML, CHATILA TA: The association of atopy with a gain-of-function mutation in the α-subunit of the IL-4 receptor. N. Engl. J. Med. (1997) 337:1720-1725.
10. CHANG TW: The pharmacological basis of anti-IgE therapy. Nature Biotechnol. (2000) 18:157-162.
11. RAJAKULASINGAM K, DURHAM SR, O'BRIEN F et al.: Enhanced expression of high-affinity IgE receptor (FcERI) α chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells. J. Allergy Clin. Immunol. (1997) 100:78-86.
12. BACHARIER LB, GERA RS: Regulation of IgE synthesis: the molecular basis and implications for clinical modulation. Allergy Asthma Proc. (1999) 20:1-8.
13. VERCELLI D, JABARA HH, ARAI K, GEHA RS: Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens. J. Exp. Med. (1989) 169:1295-1307.
14. HELM BA, SPIVEY AC, PADLAN EA: Peptide blocking of IgE/receptor interaction: possibilities and pitfalls. Allergy (1997) 52:1155-1169.
15. JARDIEU P: Anti-IgE therapy. Curr. Opin. Immunol. (1995) 7:779-782.
16. KITANI S, KRAFT D, FISCHLER C, MERGENHAGEN SE, SIRAGANIAN RP: Inhibition of allergic reactions with monoclonal antibody to the high affinity IgE receptor. J. Immunol. (1988) 140:2585-2588.
17. RABA S, NISONOFF A: Inhibition of IgE synthesis by anti-IgE: role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE. Proc. Natl. Acad. Sci. USA (1990) 87:3363-3367.
18. VAN NEERVEN RJ, VAN ROOMEN CP, THOMAS WR, DE BOER M, KNOL EF, DAVIS FM: Humanized anti-IgE mAb Hu-901 prevents the activation of allergen-specific T cells. Int. Arch. Allergy Immunol. (2001) 124:400-402.
19. PRESTA LG, LAHR SJ, SHIELDS RL et al.: Humanization of an antibody directed against IgE. J. Immunol. (1993) 151:2623-2632.
20. CORNE J, DJUKANOVIC R, THOMAS L et al.: The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J. Clin. Invest. (1997) 99:879-887.
21. YAMAGUCHI M, LANTZ CS, OETTGEN HC et al.: IgE enhances mouse mast cell Fc(E)RI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. J. Exp. Med. (1997) 185:663-672.
22. MACGLASHAN D JR, XIA HZ, SCHWARTZ LB, GONG J: IgE-regulated loss, not IgE-regulated synthesis, controls expression of FcERI in human basophils. J. Leukoc. Biol. (2001) 70:207-218.
23. MACGLASHAN DW, BOCHNER BS, ADELMAN DC et al.: Down-regulation of Fc(E)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol. (1997) 158:1438-1445.
24. MACGLASHAN D, LICHTENSTEIN LM, MCKENZIE-WHITE J et al.: Upregulation of FcERI on human basophils by IgE antibody is mediated by interaction of IgE with FcERI. J. Allergy Clin. Immunol. (1999) 104:492-498.
25. KOPP MV, BRAUBURGER J, RIEDINGER F et al.: The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J. Allergy Clin. Immunol. (2002) 110:728-735.
26. DJUKANOVIC R, WILSON SJ, KRAFT M et al.: Effect of treatment with anti-IgE antibody (omalizumab) on airway inflammation in mild atopic asthma. Am. J. Respir. Crit. Care Med. (2003) 167(Suppl.) A703.
27. BOULET LP, CHAPMAN KR, COTE J et al.: Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response [see comments]. Am. J. Respir. Crit. Care Med. (1997) 155:1835-1840.
28. FAHY JV, FLEMING HE, WONG HH et al.: The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects [see comments]. Am. J. Respir. Crit. Care Med. (1997) 155:1828-1834.
29. MILGROM H, FICK RB, SU JQ et al.: Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N. Engl. J. Med. (1999) 341:1966-1973.
30. SOLER M, MATZ J, TOWNLEY R et al.: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. (2001) 18:254-261.
31. BUSSE W, CORREN J, LANIER BQ et al.: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. (2001) 108:184-190.
32. FINN A, GROSS G, VAN BAVEL J et al.: Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J. Allergy Clin. Immunol. (2003) 111:278-284.
33. BUHL R, HANF G, SOLER M et al.: The anti-IgE antibody ornalizumab improves asthma-related quality of life in patients with allergic asthma. Eur. Respir. J. (2002) 20:1088-1094.
34. BUSSE W, CORREN J, LANIER BQ et al.: Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. (2001) 108:184-190.
35. SOLER M, MATZ J, TOWNLEY R et al.: The anti-IgE antibody ornalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. (2001) 18:254-261.
36. HOLGATE ST, CHUCHALIN A, HERBERT D, LOTVALL J, CHUNG KF, BOUSQUET J: Omalizumab (Xolair, rhumab-E25), a novel therapy for severe allergic asthma. Am. J. Respir. Crit. Care Med. (2001) 163(Suppl.):A812.
37. HOLGATE ST, BOUSQUET J, WENZEL S, FOX H, LIU J, CASTELLSAGUE J: Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr. Med. Res. Opin. (2001) 17:233-240.
38. MILGROM H, BERGER W. NAYAK A et al.: Treatment of childhood asthma with anti-immunoglobulin e antibody (omalizumab). Pediatrics (2001) 108:E36.
39. CORREN J, CASALE T, DENIZ Y, ASHBY M: Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J. Allergy Clin. Immunol. (2003) 111:87-90.
40. CHUNG KF, KUNKEL G, RAMOS S, AYRE G, FOX H, BLOGG M: Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly-controlled moderate-to-severe allergic asthma. Eur. Respir. J. (2003) 22(Suppl. 45):S203
41. LEMANSKE RF Jr, NAYAK A, MCALARY M, EVERHARD F, FOWLER-TAYLOR A, GUPTA N: Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics (2002) 110:E55.
42. ADELROTH E, RAK S, HAAHTELA T et al.: Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. (2000) 106:253-259.
43. CASALE TB, BERNSTEIN IL, BUSSE WW et al.: Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J. Allergy Clin. Immunol. (1997) 100:110-121.
44. CASALE TB, CONDEMI J, LAFORCE C et al.: Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA (2001) 286:2956-2967.
45. VIGNOLA M, BOUSQUET J, MASPERO J, FOX H, HEDGECOCK S, BLOGG M: Treatment of co-morbid allergic asthma and perennial allergic rhinitis with the anti-IgE agent. omalizumab. Eur. Respir. J. (2003) 22(Suppl. 45):S203.
46. KUEHR J, BRAUBURGER J, ZIELEN S et al.: Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J. Allergy Clin. Immunol. (2002) 109:274-280.
47. LEUNG DY, SAMPSON HA, YUNGINGER JW et al.: Effect of anti-IgE therapy in patients with peanut allergy. N. Engl. J. Med. (2003) 348:986-993.